Publications & Meeting Contributions

Publications & science

2024

ETOP 10-16 BOOSTER

xx. Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, and Stahel RA. 2024. ctDNA dynamics and mechanisms of acquired resistance in patients treated with osimertinib with or without bevacizumab from the randomised phase II ETOP-BOOSTER trial. Clin Cancer Res. doi:10.1158/1078-0432.ccr-24-0932. Epub 2024 September 09. (ETOP 10-16 BOOSTER) (Journal Impact Factor 10.4)

ETOP Lungscape

xx. Speel EM, Dafni U, Thunnissen E, Rüschoff, JH, O'Brien C, Kowalski J, Kerr KM, Bubendorf L, Sansano I, Joseph L, Kriegsmann M, Navarro A, Monkhorst K, Bille Madsen L, Hernandez Losa J, Biernat W, Stenzinger A, Rüland A, Hillen LM, Marti N, Molina-Vila MA, Dellaporta T, Kammler R, Peters S, Stahel RA, Finn SP, and Radonic T. 2024. ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project. 2024 Lung cancer 194:107860. doi: 10.1016/j.lungcan.2024.107860. Epub 2024 July 14. (ETOP Lungscape) (Journal Impact Factor 4.702)

ADC Workshop 2023

38. Peters S, Loi S, André F, Chandarlapaty S, Felip E, Finn SP, Jänne PA, Kerr KM, Munzone E, Passaro A, Pérol M, Smit EF, Swanton C, Viale G, and Stahel RA. 2024. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation. Ann Oncol, 35(7): 607-629. (ETOP General) (Journal Impact Factor 56.7)

2023

ETOP 9-15 PROMISE-meso

37. Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, and Stahel RA. 2023. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma. J Immunother Cancer, 11(10). (ETOP 9-15 PROMISE-meso) (Journal Impact Factor 10.9)

ETOP MESOSCAPE

36. Opitz I, Bille A, Dafni U, Nackaerts K, Ampollini L, de Perrot M, Brcic L, Nadal E, Syrigos K, Gray SG, Aerts J, Curioni-Fontecedro A, Rüschoff J. H, Monkhorst K, Weynand B, Silini EM, Bavaghar-Zaeimi F, Jakopovic M, Llatjos R, Tsimpouki S, Finn SP, von der Thüsen J, Marti N, Dimopoulou G, Kammler R, Peters S, Stahel RA, Falcoz PE, Brunelli A, & Baas P. 2023. European Epidemiology of Pleural Mesothelioma – Real-life data from a joint analysis of the Mesoscape database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma database. J Thorac Oncol, 18(9): 1233-1247. Epub 2023 June 2023. (ETOP MESOSCAPE) (Journal Impact Factor 20.121)

ETOP 11-16 NIVOTHYM

35. Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC, Popat S, Janssens A, Gervais R, Hochstenbag M, Silva M, Burger IA, Prosch H, Stahel R, Xenophontos E, Pretzenbaher Y, Neven A, & Peters S. 2023. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open, 8(3). doi: 10.1016/j.esmoop.2023.101576. (ETOP 11-16 NIVOTHYM) (Journal Impact Factor 6.883)

ETOP 05-12 SPLENDOUR

34. Peters S, Letovanec I, Mauer, M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth,A, Pokharel S, Reinmuth N, Majem Tarruella M, Casas-Martin J, Tsourti Z, Marti N, Kammler R, Danson S, O'Brien M, and Stahel RA. 2023. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. Lung Cancer 2023,175:141-151. (ETOP 05-12 SPLENDOUR) (Journal Impact Factor 4.702)

2022

ETOP 8-15 PEARLS

33. O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, and Peters S. 2022. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022, 23(10): 1274-1286. 10.1016/s1470-2045(22)00518-6. Epub 2022 September 16. (ETOP 8-15 PEARLS) (Journal Impact Factor 54.433).

ETOP Mesoscape

32. Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thüsen J, Marti N, Vervita K, Kammler R, Peters S, Stahel RA, Baas P, Opitz I, and for the ETOP Mesoscape consortium. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project. Mod Pathol 2022; 35(12): 1888-1899. doi: 10.1038/s41379-022-01145-0. Epub 2022 September 17. (ETOP Mesoscape) (Journal Impact Factor 5.988).

ETOP Lungcape

31. Bubendorf L, Zoche, M., Dafni, U., Rüschoff, J. H., Prince, S. S., Marti, N., Stavrou, A., Kammler, R., Finn, S. P., Moch, H., Peters, S., and Stahel, R. A. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort. Lung Cancer 2022;174:27-35. 10.1016/j.lungcan.2022.09.014. Epub 2022 October 26 (ETOP Lungcape) (Journal Impact Factor 6.081)

ETOP 12-17 ALERT-lung

30. Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans A-MC, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J, Stahel R. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial. Lung Cancer 2022;172:94-99. doi: 10.1016/j.lungcan.2022.08.008. Epub 2022 August 12. (ETOP 12-17 ALERT-lung) (Journal Impact Factor 6.081).

ETOP 9-15 PROMISE-meso

29. Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RA. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial. Lung Cancer 2022;169:77-83. doi: 10.1016/j.lungcan.2022.05.018. Epub 2022 June 7. (ETOP 9-15 PROMISE-meso) (Journal Impact Factor 5.705).

ETOP 10-16 BOOSTER

28. Dafni U, Soo RA, Peters S, Tsourti Z, Zygoura P, Vervita K, Han JY, De Castro J, Coate L, Früh M, Hashemi SMS, Nadal E, Carcereny E, Sala MA, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO Open 2022;7(3):100507. doi: 10.1016/j.esmoop.2022.100507. Epub 2022 June 14. (ETOP 10-16 BOOSTER) (Journal Impact Factor 6.540).

General

27. Pérol M, Felip E, Dafni U, Polito L, Pal N, Tsourti Z, Ton TGN, Merritt D, Morris S, Stahel R, Peters S. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol 2022;33(5):511-521. doi: 10.1016/j.annonc.2022.02.008. Epub 2022 February 27. (ETOP General) (Journal Impact Factor 32.976).

ETOP 10-16 BOOSTER

26. Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol 2022;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 November 29. (ETOP 10-16 BOOSTER) (Journal Impact Factor 32.976).

ETOP 4-12 STIMULI

25. Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Mollá A, Gervais R, López Vivanco G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, González Larriba JL, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel RA, Le Pechoux C, De Ruysscher D. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol 2022;33(1):67-79. doi: 10.1016/j.annonc.2021.09.011. Epub 2021 September 26. (ETOP 4-12 STIMULI) (Journal Impact Factor 32.976).

2021

ETOP 5-12 SPLENDOUR

24. Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe H-S, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung Cancer 2021;161:76-85. doi: 10.1016/j.lungcan.2021.09.002. Epub 2021 September 9. (ETOP 5-12 SPLENDOUR) (Journal Impact Factor 5.705).

ETOP Lungscape

23. Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, Madsen LB, Biernat W, Verbeken E, Hernandez-Losa J, Marchetti A, Cheney R, Warth A, Speel EM, Quinn AM, Monkhorst K, Jantus-Lewintre E, Tischler V, Marti N, Dimopoulou G, Molina-Vila MA, Kammler R, Kerr KM, Peters S, Stahel RA. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol 2021;16(6):990-1002. doi: 10.1016/j.jtho.2021.02.016. Epub 2021 March 2. (ETOP Lungscape) (Journal Impact Factor 15.609).

ETOP 6-14 NICOLAS

22. Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, Ruysscher D. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14). J Thorac Oncol 2021;16(2):278-288. doi: 10.1016/j.jtho.2020.10.129. Epub 2020 November 15. (ETOP 6-14 NICOLAS) (Journal Impact Factor 15.609).

2020

ETOP 9-15 PROMISE-meso

21. Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur WD, López Castro R, García Campelo R, Rusakiewicz S, Letovanec I, Polydoropoulou V, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Peters S, Stahel RA. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 2020;31(12):1734-1745. doi: 10.1016/j.annonc.2020.09.009. (ETOP 9-15 PROMISE-meso) (Journal Impact Factor 18.274).

ETOP 5-12 SPLENDOUR

20. Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, von Moos R, Zielinski C, Provencio M, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, Besse B, Rabaglio M, O'Brien MER, Stahel RA. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. J Thorac Oncol 2020;15(10):1647-1656. doi: 10.1016/j.jtho.2020.06.011. Epub 2020 June 23. (ETOP 5-12 SPLENDOUR) (Journal Impact Factor 13.357).

General

19. Stahel RA, Lacombe D, Cardoso F, Casali PG, Negrouk A, Marais R, Hiltbrunner A, Vyas M. Current models, challenges and best practices for work conducted between European academic cooperative groups and industry. ESMO Open 2020;5(2):1-12. doi: 10.1136/esmoopen-2019-000628. Epub 2020 March 28. (ETOP General) (Journal Impact Factor 5.329).

ETOP 2-11 BELIEF

18. Molina-Vila M-A, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-las-Casas C, Felip E, Fontecedro AC, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell R. Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. J Thorac Oncol 2020;15(3):416-425. doi: 10.1016/j.jtho.2019.11.023. Epub 2019 November 18 (ETOP 2-11 BELIEF) (Journal Impact Factor 13.357).

ETOP Lungscape

17. Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel E-JM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA, for the European Thoracic Oncology Platform Lungscape Consortium. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. Mod Pathol 2020;33:792–801. doi: 10.1038/s41379-019-0383-9. (ETOP Lungscape) (Journal Impact Factor 5.988).

2019

ETOP Fixation Effects

16. Van Seijen M, Brcic L, Gonzales AN, Sansano I, Bendek M, Brcic I, Lissenberg-Witte B, Korkmaz HI, Geiger T, Kammler R, Stahel R, Thunnissen E. Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen. Virchows Arch 2019;475(2):191-199. doi: 10.1007/s00428-019-02595-9. (ETOP Fixation Effects) (Journal Impact Factor 2.935).

General

15. Dafni U, Tsourti Z, Vervita K, Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer 2019;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. (ETOP General) (Journal Impact Factor 4.696).

ETOP 6-14 NICOLAS

14. Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer - The ETOP NICOLAS trial. Lung Cancer 2019;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. (ETOP 6-14 NICOLAS) (Journal Impact Factor 4.696).

ETOP 7-14 NICHE

13. Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasag B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S. Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol 2019;14(6):1086-1094. doi: 10.1016/j.jtho.2019.02.017. (ETOP 7-14 NICHE) (Journal Impact Factor 12.46).

ETOP Lungscape

12. Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E-JM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans A-M, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer 2019;131:95-103. doi: 10.1016/j.lungcan.2019.03.012. (ETOP Lungscape) (Journal Impact Factor 4.696).

2018

ETOP Lungscape

11. Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. J Thorac Oncol 2018;13(12):1851-1863. doi: 10.1016/j.jtho.2018.08.2034. (ETOP Lungscape) (Journal Impact Factor 10.34).

ETOP Lungscape

10. Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol 2018;13(3):413-425. doi: 10.1016/j.jtho.2017.11.117. (ETOP Lungscape) (Journal Impact Factor 10.34).

ETOP Lungscape

9. Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Ann Oncol 2018;29(1):200-208. doi: 10.1093/annonc/mdx629. (ETOP Lungscape) (Journal Impact Factor 13.93).

2017

ETOP Lungscape

8. Bubendorf L, Dafni U, Schobel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer 2017;111:143-149. doi: 10.1016/j.lungcan.2017.07.021. (ETOP Lungscape) (Journal Impact Factor 4.717).

ETOP 2-11 BELIEF

7. Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massuti B, Palmero R, Aix SP, Carcereny E, Fruh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gomez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. (ETOP 2-11 BELIEF) (Journal Impact Factor 19.287).

ETOP 3-12 EMPHASIS-lung

6. Peters S, Stahel RA, Dafni U, Ponce Aix S, Massuti B, Gautschi O, Coate L, Lopez Martin A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal O, Palmero Sanchez R, Villa Guzman JC, Collado Martin R, Peralta S, Insa A, Summers Y, Lang I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. J Thorac Oncol 2017;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. (ETOP 3-12 EMPHASIS-lung) (Journal Impact Factor 6.595).

2014

ETOP Lungscape

5. Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol 2014;9(11):1675-1684. doi: 10.1097/JTO.0320. (ETOP Lungscape) (Journal Impact Factor 5.282).

ETOP Lungscape

4. Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernandez-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 2014;32(25):2780-2787. doi: 10.1200/JCO.2013.54.5921. (ETOP Lungscape) (Journal Impact Factor 18.443).

ETOP Lungscape

3. Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel R, Thunnissen E. Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br J Cancer 2014;111(2):413-420. doi: 10.1038/bjc.2014.353. (ETOP Lungscape) (Journal Impact Factor 5.609).

2011

General

2. Gridelli C, Stahel R, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P, Rossi A, de Marinis F. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer 2011;74(3):544-548. doi: 10.1016/j.lungcan.2011.08.013. (ETOP General) (Journal Impact Factor 4.157).

2010

General

1. Stahel R, Baas P, Faivre-Finn C, Dooms C, Passlick B, Mazieres J, Cappuzzo F, Fruh M, Sorensen JB, Blackhall F, Taron M, Gridelli C, O'Byrne K, Rosell R. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer 2010;68(1):121-124. doi: 10.1016/j.lungcan.2010.01.010. (ETOP General) (Journal Impact Factor 3.777).

2024

ETOP 19-21 USZ-STRIKE

51. Weller M, Rhun EL, Giacomo AMD, Mayinger M, Roschitzki H, Guckenberger M, Ruepp B, Dummer R, Danfi R, Maio M, and Stahel R. 2024. OCTS-02 ETOP 19-21 USZ-STRIKE: Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer. Presented at the 2024 SNO/ASCO CNS Metastases Conference, Denver, Colorado, USA. Neuro-Oncology Advances 2024;6:i26-i. (ETOP 19-21 USZ-STRIKE) (Journal Impact Factor 15.9).

ETOP 14-18 CHESS

50. Guckenberger M, Opitz I, Dellaporta MT, Curioni-Fontecedro A, Frauenfelder T, Cerciello F, Sullivan I, Hendriks L, Dorta M, Callejo A, Aerts J, Addeo A, Dingemans A-M, Pasello G, Provencio M, Ribi K, de Marinis F, Mederos N, Roschitzki-Voser H, Ruepp B, Kammler R, Tsourti Z, Peters S, and Stahel RA. 2024. Multimodality treatment in synchronous oligometastatic NSCLC: final analysis of the ETOP CHESS trial Presented at the ESTRO 2024. Radiotherapy and Oncology, 194: S1586-S1588. (ETOP 14-18 CHESS) (Journal Impact Factor 5.4).

ETOP 4-12 STIMULI

49. Homicsko K, Abdelhamid K, Vervita K, Marcone R, Andrade J, Becker-Commissaris A, Pujol J-L, Popat S, Reck M, Pechoux CL, Ruysscher DD, Kammler R, Finn SP, Stahel RA, and Peters S. 2024. Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer. Presented at the ASCO Annual Meeting 2024. J Clin Oncol 2024, 42(16_suppl): 8103-8103. (ETOP 4-12 STIMULI) (Journal Impact Factor 32.956)

ETOP 13-18 BEAT-meso

48. Popat S, Felip E, Dafni U, Pope A, Perez SC, Shah RNH, Marinis Fd, Smith LC, Caro RB, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Schaer S, Prince SS, Roschitzki-Voser H, Ruepp B, Peters S, Stahel RA, and for the ETOP 13-18 BEAT-meso Collaborators. BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial. Presented at the ASCO Annual Meeting 2024. J Clin Oncol 2024, 42(17_suppl):LBA8002-LBA8002..doi: 10.1200/JCO.2024.42.17_suppl.LBA800 (ETOP 13-18 BEAT-meso) (Journal Impact Factor 32.956)

ETOP 15-18 ABC-lung

47. Frueh M, Soo RA, Vervita A, Cho BC, Majem M, Rodriguez Abreu D, Callejo Perez A, Moran Bueno MT, Domine Gomez M, Provencio Pulla M, Addeo A, Han JY, Ortega Granado, ALO, Ribi K, Roschitzki-Vose, H, Ruepp B, Haberecker M, Dafni U, Peters S, and Stahel RA. 2024. 12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II. Presented at the European Lung Cancer Congress (ELCC) 2024 in Prague. ESMO open. (ETOP ABC-lung trial. 15-18 ABC-lung) (Journal Impact Factor 5.329)

2023

ETOP 9-15 PROMISE-meso

46. Homicsko K, Zygoura G, Tissot S, Popat S, Curioni-Fontecedro A, Dellaporta T, O'Brien M, Pope A, Shah RNH, Kammler R, Finn SP, Coukos G, Peters S, and Stahel RA. 2023. Association of tertiary lymphoid structures with outcomes from PD-1 inhibition in advanced malignant pleural mesothelioma. Presented at the ASCO Annual Meeting 2023. J Clin Oncol 2023, 41(16_suppl): e20545-e20545. doi: 10.1200/JCO.2023.41.16_suppl.e20545. (ETOP 9-15 PROMISE-meso) (Journal Impact Factor 32.956)

ETOP Lungscape

45. Speel EJM, Radonic T, Dafni U, Thunnissen E, Rüschoff JH, Kowalski J, Kerr KM, Bubendorf L, Valero IS, Joseph L, Navarro A, Monkhorst K, Madsen LB, Losa JH, Biernat W, Dellaporta T, Kammler R, Peters S, Stahel RA, and Finn SP. 2023. 191P ROS1 fusions in resected stage I-III adenocarcinoma (ADC): A Lungscape ETOP study. Presented at the ELCC 2023 in Copenhagen. J Thorac Oncol 2023, 18(4): S144-S145. doi: 10.1016/S1556-0864(23)00444-6 (ETOP Lungscape) (Journal Impact Factor 13.357).

ETOP 10-16 BOOSTER

44. Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Gonzalez MAS, Coate L, Pulla MP, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, and Stahel RA. 2023. 16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial. Presented at the ELCC 2023 in Copenhagen. J Thorac Oncol 2023, 18(4): S49-S50. doi: 10.1016/S1556-0864(23)00270-8. (ETOP 10-16 BOOSTER) (Journal Impact Factor 13.357).

2022

ETOP 9-15 PROMISE-meso

43. Homicsko, K, Zygoura, P, Tissot, S, Norkin, M, Popat, S, Curioni-Fontecedro, A, O'Brien, MER, Pope, T, Shah, R, Kammler, R, Finn, SP, Coukos, G, Dafni, U, Peters, S, and Stahel, RA. 2022. 11P Association of VISTA-expressing CD66b-positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma. Presented at the ESMO Immuno-Oncology and Technology Congress (IOTECH) December 2022.Immuno-Oncology and Technology, 16.Supplement 1, 100116. Doi: 10.1016/j.iotech.2022.100116. (ETOP 9-15 PROMISE-meso) (Journal Impact Factor)

ETOP 8-15 PEARLS

42. Paz-Ares L, O'Brien MER, Mauer M, Dafni U, Oselin K, Havel L, Esteban Gonzalez E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Keller SM, Jha N, Marreaud SI, Stahel RA, Peters S, Besse B. Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 study. Presented at the ESMO Virtual Plenary March 2022. Ann Oncol 2022;33(4):451-453. doi: 10.1016/j.annonc.2022.02.224. (ETOP 8-15 PEARLS) (Journal Impact Factor 32.976).

ETOP 10-16 BOOSTER

41. Dafni U, Soo RA, Peters S, Tsourti Z, Vervita K, Han JY, De Castro J, Coate L, Früh M, Hashemi SMS, Nadal E, Carcereny E, Angeles Sala González M, Bernabé Caro R, Provencio Pulla M, Cuffe S, Ruepp B, Roschitzki-Voser H, Rosell R, Stahel RA. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis. Presented at the ELCC 2022, virtual. Ann Oncol 2022;33(Suppl2):S46-S47. doi: 10.1016/j.annonc.2022.02.041. (ETOP 10-16 BOOSTER) (Journal Impact Factor 32.976).

2021

ETOP 10-16 BOOSTER

40. Soo R, Han J-Y, Dimopoulou G, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabe R, Coate L, Provencio M, García Campelo R, Cuffe S, Hashemi S, Früh M, Ruepp B, Roschitzki-Voser H, Stahel R, Peters S. A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial. Presented at the ESMO Virtual Plenary 2021 & Virtual Plenary Debate during ESMO Congress 2021. Ann Oncol 2021;32(7):942-944. doi: 10.1016/j.annonc.2021.04.010. (ETOP 10-16 BOOSTER) (Journal Impact Factor 32.976).

General

39. Peters S, Dafni U, Perol M, Felip E, Polito L, Pal N, Ton TGN, Merritt D, Morris S, Stahel RA. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data. Presented at the ESMO Virtual Plenary April 2021. Ann Oncol 2021;32(5):687-688. doi: 10.1016/j.annonc.2021.03.195. (ETOP General) (Journal Impact Factor 32.976).

ETOP Mesoscape

38. Opitz I, Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, Ampollini L, De Perrot M, Brcic L, Nadal E, Gray S, Aerts J, Verbeken E, Silini E, Zaeimi F, Samarzija M, Llatjos R, Tsimpoukis S, Von Der Thüsen J, Finn S, Monkhorst K, Marti N, Dimopoulou G, Kammler R, Peters S, Baas P, Stahel R. Phosphorylated Ribosomal Protein S6, Correlation With Characteristics and Clinical Outcome in Patients With MPM: Results from ETOP Mesoscape. Presented at the WCLC 2020 in Singapore. J Thorac Oncol 2021;16(3):152. doi: 10.1016/j.jtho.2021.01.174. (ETOP Mesoscape) (Journal Impact Factor 15.609).

2020

ETOP 14-18 CHESS

37. Guckenberger M, Opitz I, Dafni U, Fontecedro AC, Scherz A, Elicin O, Addeo A, Aerts JGJV, Dingemans AM, Hendriks L, Munarriz BJ, Juan-Vidal O, Sullivan I, Valdivia J, Piguet AC, Roschitzki-Voser H, Ehrbar S, Baumgartl M, Peters S, Stahel RA. Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial. Presented at the ESMO Virtual Congress 2020. Ann Oncol 2020;31(Suppl4):895-896. doi: 10.1016/j.annonc.2020.08.1731. (ETOP 14-18 CHESS) (Journal Impact Factor 32.976).

ETOP 4-12 STIMULI

36. Peters S, Pujol JL, Dafni U, Dómine M, Becker A, Andrade J, Curioni-Fontecedro A, Molinier O, Moro-Sibilot D, Nackaerts K, Mollá AI, López Vivanco G, Madelaine J, Popat S, Reck M, Roschitzki-Voser H, Mitchell P, De Ruysscher D, Le Pechoux C, Stahel R. Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial. Presented at the ESMO Virtual Congress 2020. Ann Oncol 2020;31(Suppl4):1211. doi: 10.1016/j.annonc.2020.08.2326. (ETOP 4-12 STIMULI) (Journal Impact Factor 18.274).

2019

ETOP Mesoscape

35. Opitz I, Bille A, Tsourti Z, Nakaerts K, Ampollini L, De Perrot M, Brcic L, Nadal E, Gray S, Aerts J, Verbeken E, Silini E, Zaeimi F, Samarzija M, Llatjos R, Tsimpoukis S, Van Der Thüsen JH, Finn S, Marti N, Dimopoulou G, Monkhorst K, Brunello A, Kammler R, Soltermann A, Falcoz P, Baas P, Stahel R. Realtime Data from Europe ETOP / ESTS Database. Presented at the WCLC 2019 in Barcelona, Spain. J Thorac Oncol 2019;14(10):93-94. doi: 10.1016/j.jtho.2019.08.210. (ETOP Mesoscape) (Journal Impact Factor 12.46).

ETOP 9-15 PROMISE-meso

34. Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R, O’Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur W-D, López Castro R, García Campelo R, Roschitzki-Voser H, Ruepp B, Rusakiewicz S, Peters S, Stahel RA. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Presented at the ESMO Congress 2019 in Barcelona, Spain. Ann Oncol 2019;30(Suppl5):931. doi: 10.1093/annonc/mdz394.091. (ETOP 9-15 PROMISE-meso) (Journal Impact Factor 18.274).

ETOP 6-14 NICOLAS

33. Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet A-C, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste JF, De Ruysscher D. Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial. Presented at the ESMO Congress 2019 in Barcelona, Spain. Ann Oncol 2019;30(Suppl5):591. doi: 10.1093/annonc/mdz259. (ETOP 6-14 NICOLAS) (Journal Impact Factor 18.274).

2018

ETOP 5-12 PEARLS

32. Peters S, Danson SJ, Hasan B, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Massutí B, Coate L, von Moos R, Zielinski CC, De Maio E, O’Brien M, Roschitzki-Voser H, Dafni U, Stahel RA. A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. Presented at the ESMO Congress 2018 in Munich, Germany. Ann Oncol 2018;29(Suppl 8):498. doi: 10.1093/annonc/mdy292.008. (ETOP 5-12 PEARLS) (Journal Impact Factor 14.196).

ETOP 2-11 BELIEF

31. Curioni A, Stahel RA, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Karachaliou N, Rosell R, Roschitzki-Voser H, Kammler R, Kassapian M, Felip E, Dafni U, Molina M-A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce S. Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. Presented at the ESMO Congress 2018 in Munich, Germany. Ann Oncol 2018;29(Suppl8):513. doi: 10.1093/annonc/mdy292.044. (ETOP 2-11 BELIEF) (Journal Impact Factor 14.196).

ETOP 6-14 NICOLAS

30. Peters S, De Ruysscher D, Dafni U, Felip E, Guckenberger M, Vansteenkiste JF, Huber R, Nadal E, Irigoyen A, Becker A, Piguet A-C, Kassapian M, Gasca-Ruchti A, Martinez Marti A, Andratschke N, Lambrecht M, Belka C, Roschitzki-Voser H, Stahel RA. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial. Presented at the ASCO Annual Meeting 2018 in Chicago, IL, USA. J Clin Oncol 2018;36(Suppl15):8510. doi: 10.1200/JCO.2018.36.15_suppl.8510. (ETOP 6-14 NICOLAS) (Journal Impact Factor 26.36).

ETOP Lungscape

29. Van Seijen M, Brcic L, Navarro A, Sansano I, Béndek M, Witte B, Brcic I, Kammler R, Stahel RA, Thunnissen E. Influence of delayed and prolonged fixation on the evaluation of immunohistochemical staining on pulmonary resection specimen. Presented at ELCC 2018 in Geneva, Switzerland. J Thorac Oncol 2018;13(4):11. doi: 10.1016/S1556-0864(18)30301-0. (ETOP Lungscape) (Journal Impact Factor 10.34).

2017

ETOP Lungscape

28. Thunnissen E, Dafni U, Bubendorf L, Warth A, Biernat W, Pokharel S, Dziadziuszko R, Dienemann H, Cheney R, Marti N, Kassapian M, Finn S, Kerr K, Kammler R, Stahel R, Peters S, ETOP Lungscape. Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort. Presented at the WCLC 2017 in Yokohoma, Japan. J Thorac Oncol 2017;12(11):1821-1822. doi: 10.1016/j.jtho.2017.09.494. (ETOP Lungscape) (Journal Impact Factor 6.595).

ETOP Lungscape

27. Kerr KM, Thunnissen E, Dafni U, Soltermann A, Finn S, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E-J, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Polydoropoulou V, Kammler R, Peters S, Stahel RA. Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Presented at the ESMO Congress 2017 in Madrid, Spain. Ann Oncol 2017;28(Suppl5):573–594. doi: 10.1093/annonc/mdx390.002. (ETOP Lungscape) (Journal Impact Factor 13.93).

ETOP Lungscape

26. Kerr K, Thunnissen E, Dafni U, Soltermann A, Finn S, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E-J, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Bille Madsen L, Polydoropoulou V, Kammler R, Peters S, Stahel RA. Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA. J Clin Oncol 2017;35(Suppl15):8516. doi: 10.1200/JCO.2017.35.15_suppl.8516. (ETOP Lungscape) (Journal Impact Factor 24.008).

ETOP 7-14 NICHE

25. Smit EF, Peters S, Dziadziuszko R, Dafni U, Wolf J, Wasąg B, Biernat W, Finn S, Kammler R, Tsourti Z, Rabaglio-Poretti M, Ruepp BU, Roschitzki-Voser H, Stahel RA, Felip E. A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial. Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA. J Clin Oncol 2017;35(Suppl15):9070-9070. doi: 10.1200/JCO.2017.35.15_suppl.9070. (ETOP 7-14 NICHE) (Journal Impact Factor 24.008).)

ETOP 6-14 NICOLAS

24. Peters S, Stahel RA, Kassapian M, Guckenberger M, Felip E, De Langen AJ, Huber R, Piguet A-C, Roschitzki-Voser H, De Ruysscher D. A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial. Presented at ELCC 2017 in Geneva, Switzerland. Ann Oncol 2017;28(Suppl2):27. doi: 10.1093/annonc/mdx092.009. (ETOP 6-14 NICOLAS) (Journal Impact Factor 13.93).

ETOP Lungscape

23. Finn S, Letovanec I, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel E-J, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernández-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Stahel R. Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project. Presented at the WCLC 2016 in Vienna, Austria. J Thorac Oncol 2017;12(11,Suppl1):501-502. doi: 10.1016/j.jtho.2016.11.608. (ETOP Lungscape) (Journal Impact Factor 6.595).

2016

ETOP 4-12 STIMULI

22. De Ruysscher D, Pujol J-L, Popat S, Reck M, Le Pechoux C, Liston A, Speiser D, Coukos G, Kammler R, Dafni U, Tsourti Z, Roschitzki H, Finlayson M, Piguet A-C, Ruepp B, Maibach R, Stahel RA, Peters S. STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT. Presented at the ESMO Congress 2016 in Copenhagen, Denmark. Ann Oncol 2016;27(Suppl6):493–496. doi: 10.1093/annonc/mdw389.08. (ETOP 4-12 STIMULI) (Journal Impact Factor 11.855).

ETOP Lungscape

21. Soltermann A, Rulle U, Dafni O, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen Bille L, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn S, Kammler R, Schulze K, Bubendorf L, Stahel RA. Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Presented at the ESMO Congress 2016 in Copenhagen, Denmark. Ann Oncol 2016;27(Suppl6):526–544. doi: 10.1093/annonc/mdw392.07. (ETOP Lungscape) (Journal Impact Factor 11.855).

ETOP 2-11 BELIEF

20. Rosell R, Karachaliou N, Giménez-Capitán A, Codony-Servat C, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Ponce-Aix S, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Favaretto A, Kammler R, Dafni U, Tsourti Z, Molina-Vila MA, Stahel RA. The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial. Presented at the Annual Meeting of the AACR 2016, New Orleans, LA, USA. Cancer Res 2016;76(14,Suppl):269-269. doi: 10.1158/1538-7445.am2016-269. (ETOP 2-11 BELIEF) (Journal Impact Factor 9.122).

2015

ETOP 2-11 BELIEF

19. Stahel RA, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix SP, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Carcereny E, Sanchez Ronco M, Molina MA, Rosell R. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Presented at the European Cancer Congress 2015 in Vienna, Austria. Eur J Cancer 2015;51(Suppl3):711-712. doi: 10.1016/S0959-8049(15)30068-X. (ETOP 2-11 BELIEF) (Journal Impact Factor 5.417).

ETOP Lungscape

18. Kerr K, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Gately K, Biernat W, Vliegen L, Hernandez Losa J, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Molina MA, Shames DS, Peters S, Stahel R. Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project. Presented at the European Cancer Congress 2015 in Vienna, Austria. Eur J Cancer 2015;51(Suppl3):595-596. doi: 10.1016/S0959-8049(16)31647-1. (ETOP Lungscape) (Journal Impact Factor 5.417).

ETOP Lungscape

17. Bubendorf L, Dafni U, Finn S, Warth A, Savic S, Thunnissen E, Sejda A, Verbeken E, Tischler V, Marchetti A, Sansano I, Speel E, Cheney R, Nonaka D, Monkhorst K, Di Lorito A, Consuelo Calabuig M, Reidy M, Hager H, Mathieson W, Martorell M, Baas P, Dienemann H, Smit E, Blackhall F, Dingemans A, Felip E, Adjei A, Meldgaard P, Weder W, Vansteenkiste J, Dziadziuszko R, Tsourti Z, Kerr K, Schulze K, Das-Gupta A, Peters S, Stahel R. Prevalence and Clinical Association of MET Gene Amplification in Patients with NSCLC: Results from the ETOP Lungscape Project. Presented at the WCLC 2015 in Denver, CO, USA. J Thorac Oncol 2015;10(9,Suppl2):173-260. doi: 10.1016/S1556-0864(16)30010-7. (ETOP Lungscape) (Journal Impact Factor 5.282).

ETOP Lungscape

16. Letovanec I, Peters S, Tsourti Z, Finn S, Soltermann A, Bubendorf L, Speel E, Marchetti A, Nonaka D, Hager H, Martorell M, Monkhorst K, Sejda A, Cheney R, Sansano I, Verbeken E, Tischler V, Savic S, Di Lorito A, Consuelo Calabuig M, Felip E, Adjei A, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans A, Dienemann H, Dziadziuszko R, Vansteenkiste J, Kammler R, Dafni U, Kerr K, Thunnissen E, Stahel R. Evaluation of RT-PCR Methodology for ALK Assessment in Patients with NSCLC in Europe: Results from the ETOP Lungscape Project. Presented at the WCLC 2015 in Denver, CO, USA. J Thorac Oncol 2015;10(9,Suppl2):407-760. doi: 10.1016/S1556-0864(16)30012-0. (ETOP Lungscape) (Journal Impact Factor 5.282).

ETOP 3-12 EMPHASIS

15. Peters S, Smit EF, Dafni U, Aix SP, Massuti B, Gautschi O, Coate L, Martín AL, van Heemst R, Berghmans T, Meldgaard P, Dols MC, Noguera JG, Floriani IC, Kassapian M, Kuruvilla YCK, Gasca-Ruchti A, Zielinski C, Gregorc V, Stahel RA. Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial. Presented at the ASCO Annual Meeting 2015 in Chicago, IL, USA. J Clin Oncol 2015;33(Suppl15):8049-8049. doi: 10.1200/jco.2015.33.15_suppl.8049. (ETOP 3-12 EMPHASIS) (Journal Impact Factor 18.443).

2014

ETOP Lungscape

14. Bubendorf L, Savic S, Dafni O, Tsourti Z, Tischler V, Finn S, Biernat W, Verbeken E, Hager H, Murtra N, Thunnissen E, Nonaka D, Warth A, Speel EJ, Martorell M, Schulze K, Das-Gupta A, Kerr KM, Peters S, Stahel RA. Prevalence and clinical outcomes for patients with MET protein expression in patients with non-small cell lung cancer in Europe: Results from the European Thoracic Oncology Platform Lungscape Project. Presented at the ESMO Congress 2014 in Madrid, Spain. Ann Oncol 2014;25(Suppl4):418-418. doi: 10.1093/annonc/mdu348.5. (ETOP Lungscape) (Journal Impact Factor 6.578).

2013

ETOP Lungscape

13. Peters S, Weder W, Meldgaard P, O'Byrne K, Wrona A, Dooms C, Hernandez-Losa J, Marchetti A, Nicolson M, Tan Q, Smit EF, Dingemans A-MC, Savic S, Blackhall FH, Baas P, Jantus-Lewintre E, Kerr KM, Dafni U, Rafael R, Stahel RA. The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. Presented at the ASCO Annual Meeting 2013 in Chicago, IL, USA. J Clin Oncol 2013;31(Suppl15):7514-7514. doi: 10.1200/jco.2013.31.15_suppl.7514. (ETOP Lungscape) (Journal Impact Factor 18.038).

ETOP Lungscape

12. Kerr K, Thunnissen E, Blackhall F, Dafni U, Bubendorf L, Hager H, Soltermann A, O'Byrne K, Marchetti A, Dooms C, Sejda A, Sansano I, Nonaka D, Cheney R, De Jong J, Speel E, Jantus-Lewintre E, Zhang Y, Stahel R, Peters S. ALK immunohistochemistry and fluorescence in-situ hybridization in lung adenocarcinomas from the ETOP Lungscape tumour cohort. Presented at the 15th WCLC 2013 in Sydney, Australia. J Thorac Oncol 2013;8(11,Suppl2):2-1348. doi: 10.1097/01.JTO.0000438438.14562.c8. (ETOP Lungscape) (Journal Impact Factor 5.8).

2012

ETOP Lungscape

11. Peters S, Dafni U, Bubendorf L, Meldgaard P, O'Byrne K, Wrona A, Weder W, Canela M, Malatesta S, Vansteenkiste J, Dingemans A, Nicolson M, Savic S, Baas P, Peck R, Lu S, Smit E, Jantus-Lewintre E, Rosell R, Stahel R. The European Thoracic Oncology Platform Lungscape project. A way to bridge non-small cell lung cancer molecular characteristics and clinical data. Presented at the ESMO Congress 2012 in Vienna, Austria. Ann Oncol 2012;23(Suppl 9):385. doi: 10.1093/annonc/mds407. (ETOP Lungscape) (Journal Impact Factor 7.384).

ETOP Lungscape

10. Blackhall F, Peters S, M. Kerr K, O'Byrne K, Hager H, Sejda A, Soltermann A, Dooms C, Felip E, Marchetti A, M. Speel EJ, Price N, Savić S, de Jong J, Martorell M, Thunnissen E, Bubendorf L, Dafni U, Rosell R, Stahel RA. Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: Preliminary results from the European Thoracic Oncology Platform Lungscape project. Presented at the ESMO Congress 2012 in Vienna, Austria. Ann Oncol 2012;23(Suppl9):73. doi: 10.1093/annonc/mds391. (ETOP Lungscape) (Journal Impact Factor 7.384).

General

9. Stahel R. Lung Cancer: The European Thoracic Oncology Platform. Presented at the ESMO Congress 2012 in Vienna, Austria. Ann Oncol 2012;23(Suppl9):58. doi: 10.1093/annonc/mds482. (ETOP General) (Journal Impact Factor 7.384).

ETOP Lungscape

8. Normanno N, Patton S, Blackhall F, Murray S, Kerr K, Dietel M, Filipits M, Benlloch S, Stahel R, Thunnissen E. Results of the second pilot external quality assurance scheme for somatic EGFR mutation testing in non-small cell lung cancer (NSCLC). Presented at the ESMO Congress 2012 in Vienna, Austria. Ann Oncol 2012;23(Suppl9):86. doi: 10.1016/S0923-7534(20)32779-4. (ETOP Lungscape) (Journal Impact Factor 7.384).

ETOP Lungscape

7. Thunnissen E, Kerr K, Bubendorf L, Nonaka D, Blackhall F, Kammler R, Speel E, De Jong J, Martorell M, Stahel R. External quality assessment for ALK immunohistochemistry testing in lung adenocarcinoma within the European Thoracic Oncology Platform Lungscape project. Presented at the ESMO Congress 2012 in Vienna, Austria. Ann Oncol 2012;23(Suppl9):80. doi: doi.org/10.1093/annonc/mds391. (ETOP Lungscape) (Journal Impact Factor 7.384).

ETOP Lungscape

6. Stahel R, Blackhall F, Peters S, Bubendorf L, Dafni U, Kerr K, Taron M, Thunnissen E, Weder W, Rosell R. The Lungscape project. Presented at ELCC 2012 in Geneva, Switzerland. J Thorac Oncol 2012;7(6,Suppl1):13. doi: 10.1097/JTO.0b013e318253d2ff. (ETOP Lungscape) (Journal Impact Factor 4.473).

General

5. Stahel RA, Peters S, Blackhall F, Bubendorf L, Dafni U, Kerr K, Taron M, Thunnissen E, Weder W, Smit E, Rosell R. ETOP activity in the field of biomarkers and predictors. Presented at BTOG 2012 in Dublin, Ireland. Lung Cancer 2012;77(Suppl1):16-17. doi: 10.1016/j.lungcan.2012.05.028. (ETOP General) (Journal Impact Factor 4.054).

ETOP Lungscape

4. Peters S, Blackhall F, Taron M, Rosell R, Hiltbrunner A, Maibach R, King R, Stahel R. ETOP Data system: Combining the comprehensive Lungscape database with a clinical trails platform. Presented at TAT 2012 in Amsterdam, the Netherlands. Ann Oncol 2012;23(Suppl1):41. doi: 10.1093/annonc/mds018. (ETOP Lungscape) (Journal Impact Factor 7.384).

2011

ETOP Lungscape

3. Blackhall F, Peters S, Kerr K, Kulig K, Bubendorf L, Thunnissen E, Dziadziuszko R, O’Byrne K, Baas P, Weder W, Taron M, Rosell R, Stahel R. ALK Gene Rearrangement: Prevalence and clinical outcomes in patients with non-small cell lung cancer (NSCLC) in Europe – A European Thoracic Oncology Group (ETOP) Lungcape Study. Presented at the 14th WCLC 2011 in Amsterdam, the Netherlands. J Thorac Oncol 2011;6(6,Suppl2):1529-1530. doi: 10.1097/01.JTO.0000399290.73317.eb. (ETOP Lungscape) (Journal Impact Factor 3.661).

ETOP Lungscape

2. Peters S, Blackhall F, Boffetta P, Kerr K, Taron M, Bubendorf L, Ciardiello F, Rosell R, Weder W, King R, Stahel R. Building a Comprehensive Database for the Lungscape Project: A Way to Bridge Genomics and Clinical Practice in the European Thoracic Oncology Platform (ETOP). Presented at the 14th WCLC 2011 in Amsterdam, the Netherlands. J Thorac Oncol 2011;6(6,Suppl2):994-995. doi: 10.1097/01.JTO.0000399290.73317.eb. (ETOP Lungscape) (Journal Impact Factor 3.661).

ETOP Lungscape

1. Stahel R, Blackhall F, Peters S, Kerr K, Taron M, Bubendorf L, Weder W, Boffetta P, Ciardiello F, Rosell R. Lungscape - a project of the European Thoracic Oncology Platform (ETOP). Presented at TAT 2011 in Paris, France. Ann Oncol 2011;22(Suppl3):28. doi: 10.1093/annonc/mdr106. (ETOP Lungscape) (Journal Impact Factor 6.425).